Management of chemotherapy toxicity in female breast cancer patients receiving anthracyclins ± taxanes as adjuvant treatment

Abstract

Breastcanceristhemostcommoncancerinwomenworldwide(29%ofallnewcancercases)andthe2ndleadingcauseofcancer deathinUnitedStates(Howlader etal., 2012). In2013,anestimated234,580newcasesofinvasivebreastcancerwerediagnosedinwomenintheU.S.,alsoabout40,300womenintheU.S.wereexpectedtodiein2013frombreastcancer,thoughdeathrateshavebeendecreasingsince1990(AmericanCancer Society, Cancer factsand figures2013). InEgypt,Breastcanceristhemostcommoncancerinfemales(about35.1%ofallfemalecancercases)andaleadingcauseofcancer relateddeaths(EL Bolkainyetal.,2006). Despiteoptimallocaltreatment,virtuallyallpatientswithinvasivebreastcancerhavesomeriskofsystemicrelapse.Thisriskvarieswithnumerouspatientanddiseaserelatedfactors.Therefore,allwomenwithinvasivebreastcancerstandtobenefitfromsystemictreatmenttotryandreducethisrisk.However,becauseallofthesetreatmentshavesideeffectsandpotentialrisks,theneedforsystemictreatmentmustbe assessedonan individual basis(Hafftyetal.,2009). TheEarlyBreastCancerTrialists’CollaborativeGroup(EBCTCG)meta-analysisinvolvingover 28,000 women

enrolledin60trialsofadjuvantpoly-chemotherapyversusnochemotherapydemonstratedasignificantbeneficialimpactofchemotherapyonclinicaloutcomeinearlybreastcancer.Thisstudyshowedthatadjuvantchemotherapyreducestherisk